Thomas Reiser/X
Aug 19, 2025, 14:02
Thomas Reiser Invites Clinicians to Join ISTH Survey on APS Diagnosis and Antithrombotic Treatment in Acute Ischemic Cardiac Disease
Thomas Reiser, Executive Director of International Society on Thrombosis and Haemostasis (ISTH), shared a post on X:
“Your expertise is requested!
Take this survey from the ISTH SSC Subcom. on Lupus Anticoagulant/Antiphospholipid Antibodies on APS diagnosis and antithrombotic treatment in patients with acute ischemic cardiac disease to assess current clinical practices.”
Check for more information here.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs